2. Search Result
Search Result
Results for "

COX-2-IN-50

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16726
    Polmacoxib

    CG100649

    		 COX Carbonic Anhydrase Cancer
    Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
    Polmacoxib
  • HY-120824
    Mofezolac
    1 Publications Verification

    		 COX Inflammation/Immunology
    Mofezolac, a non-steroidal anti-inflammatory drug (NSAID), is a selective, reversible and orally active COX-1 inhibitor with an IC50 of 1.44 nM. Mofezolac shows weak inhibitory activity on COX-2 (IC50 of 447 nM). Mofezolac can relieve pain and has anti-inflammatory activities .
    Mofezolac
  • HY-121537
    CAY10404

    		COX Akt Apoptosis Neurological Disease Inflammation/Immunology Cancer
    CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities .
    CAY10404
  • HY-B0367
    Lornoxicam

    Chlortenoxicam; Ro 13-9297

    		 Apoptosis COX NO Synthase Interleukin Related Prostaglandin Receptor TNF Receptor Inflammation/Immunology Cancer
    Lornoxicam (Chlortenoxicam) is an orally active oxycontin nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antipyretic and anticancer activities. Lornoxicam exhibits good inhibitory effects on both COX-1 and COX-2 (COX-1: IC50=0.005 μM; COX-2:IC50=0.008 μM) and inhibits the production of NO by iNOS (IC50=65 μM) and the proinflammatory cytokine IL-6 (IC50=54 μM). Lornoxicam also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis. Lornoxicam can be used in the study of inflammatory pain, colorectal cancer and breast cancer .
    Lornoxicam
  • HY-121679
    COX-2-IN-50

    		COX Neurological Disease
    COX-2-IN-50 is a water-soluble COX-2 inhibitor with significant analgesic activity. The solubility of COX-2-IN-50 in water reaches 20.3 mg/mL, far exceeding the 1.6 μg/mL of its precursor compound PC407. COX-2-IN-50 demonstrates good biocompatibility and is suitable for the development of injectable dosage forms. COX-2-IN-50 has proven its analgesic effect in vivo and shows potential application value .
    COX-2-IN-50
  • HY-16726R
    Polmacoxib (Standard)

    		COX Carbonic Anhydrase Cancer
    Polmacoxib (Standard) is the analytical standard of Polmacoxib. This product is intended for research and analytical applications. Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonic anhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
    Polmacoxib (Standard)
  • HY-162167
    COX-1-IN-1

    		COX Cardiovascular Disease Neurological Disease
    COX-1-IN-1 (compound 15a) is a selective inhibitor for cyclooxygenase (COX), with IC50s of 0.23 μM (COX-1) and >50 μM (COX-2), selective index (COX-2 IC50/COX-1 IC50) is 217. COX-1-IN-1 inhibits platelet aggregation .
    COX-1-IN-1
  • HY-152120
    (±)-Aiphanol

    Aiphanol

    		 COX VEGFR Inflammation/Immunology Cancer
    (±)-Aiphanol is a newly discovered stilbenolignan analog. (±)-Aiphanol exhibits significant anti-inflammatory activity, acting through inhibition of COX-1 and COX-2. The inhibitory effect on COX-1 (IC50 = 1.9 μM) is particularly strong, while the effect on COX-2 (IC50= 9.9 μM) is relatively weak .(±)-Aiphanol effectively inhibits VEGFR2 (IC50=0.92 µM). (±)-Aiphanol blocks angiogenesis and promotes apoptosis through inhibition of VEGFR2 and COX2 activity. (±)-Aiphanol is orally active .
    (±)-Aiphanol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: